Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.

Voora D, Cyr D, Lucas J, Chi JT, Dungan J, McCaffrey TA, Katz R, Newby LK, Kraus WE, Becker RC, Ortel TL, Ginsburg GS.

J Am Coll Cardiol. 2013 Oct 1;62(14):1267-1276. doi: 10.1016/j.jacc.2013.05.073. Epub 2013 Jul 3.

2.

Antiplatelet effect of aspirin in patients with coronary artery disease.

Grove EL.

Dan Med J. 2012 Sep;59(9):B4506. Review.

PMID:
22951204
3.

Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.

Karolczak K, Kamysz W, Karafova A, Drzewoski J, Watala C.

Pharmacol Res. 2013 Aug;74:7-22. doi: 10.1016/j.phrs.2013.04.010. Epub 2013 May 7.

PMID:
23665469
4.

Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.

Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G.

JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75. doi: 10.1016/j.jcin.2013.06.010.

5.

Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.

Voora D, Ortel TL, Lucas JE, Chi JT, Becker RC, Ginsburg GS.

J Thromb Thrombolysis. 2012 Apr;33(3):246-57. doi: 10.1007/s11239-012-0683-0.

6.

Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction.

Rose JJ, Voora D, Cyr DD, Lucas JE, Zaas AK, Woods CW, Newby LK, Kraus WE, Ginsburg GS.

PLoS One. 2015 Jul 20;10(7):e0132259. doi: 10.1371/journal.pone.0132259. eCollection 2015.

7.

Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.

W├╝rtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD.

JACC Cardiovasc Interv. 2010 Aug;3(8):828-35. doi: 10.1016/j.jcin.2010.05.014.

8.

Toward a genomic definition of aspirin resistance.

Bishopric NH.

J Am Coll Cardiol. 2013 Oct 1;62(14):1277-1279. doi: 10.1016/j.jacc.2013.06.024. Epub 2013 Jul 10. No abstract available.

9.

Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use.

Voora D, Horton J, Shah SH, Shaw LK, Newby LK.

Am Heart J. 2011 Jul;162(1):166-72.e1. doi: 10.1016/j.ahj.2011.03.026.

PMID:
21742104
10.

Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.

Neergaard-Petersen S, Ajjan R, Hvas AM, Hess K, Larsen SB, Kristensen SD, Grove EL.

PLoS One. 2013 Aug 19;8(8):e71150. doi: 10.1371/journal.pone.0071150. eCollection 2013.

11.

Posttreatment platelet reactivity on clopidogrel is associated with the risk of adverse events after off-pump coronary artery bypass.

Youn YN, Yi G, Lee S, Joo HC, Yoo KJ.

Am Heart J. 2014 Jun;167(6):818-25. doi: 10.1016/j.ahj.2014.01.016. Epub 2014 Mar 1.

PMID:
24890530
12.

Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.

Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD.

Circulation. 2009 Dec 22;120(25):2586-96. doi: 10.1161/CIRCULATIONAHA.109.900589. Epub 2009 Dec 7.

14.

Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction.

Ahn SG, Lee SH, Yoon JH, Kim WT, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Choe KH.

JACC Cardiovasc Interv. 2012 Mar;5(3):259-67. doi: 10.1016/j.jcin.2011.12.009.

15.

Antiplatelet effects of aspirin in chronic kidney disease patients.

Polzin A, Dannenberg L, Sansone R, Levkau B, Kelm M, Hohlfeld T, Zeus T.

J Thromb Haemost. 2016 Feb;14(2):375-80. doi: 10.1111/jth.13211. Epub 2016 Jan 25.

16.

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ.

J Am Coll Cardiol. 2003 Mar 19;41(6):961-5. Erratum in: J Am Coll Cardiol. 2006 Nov 7;48(9):1918.

17.

Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.

Good RI, McGarrity A, James TE, Miller H, McConnachie A, Goodall AH, Oldroyd KG.

Thromb Res. 2015 Jun;135(6):1140-6. doi: 10.1016/j.thromres.2015.02.021. Epub 2015 Feb 26.

PMID:
25746368
18.

Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?

Postula M, Rosiak M, Kaplon-Cieslicka A, Kondracka A, Trzepla E, Filipiak KJ, Czlonkowski A, Opolski G.

Cardiol J. 2012;19(5):494-500.

19.

Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes.

Aksu H, Ozer O, Unal H, Hobikoglu G, Norgaz T, Buturak A, Soylu O, Narin A.

Blood Coagul Fibrinolysis. 2009 Dec;20(8):686-93. doi: 10.1097/MBC.0b013e32833161ac.

PMID:
19730245
20.

Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.

Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G.

Expert Opin Pharmacother. 2015;16(12):1739-47. doi: 10.1517/14656566.2015.1056151. Epub 2015 Jun 12.

PMID:
26067422

Supplemental Content

Support Center